Evaluation of Dynamic Balance After Recovery From COVID 19 Disease

Sponsor
October 6 University (Other)
Overall Status
Completed
CT.gov ID
NCT05813886
Collaborator
(none)
25
1
12.9
1.9

Study Details

Study Description

Brief Summary

effect of post covid-19 on dynamic balance in patients after recovery from covid-19 disease.

Condition or Disease Intervention/Treatment Phase
  • Other: biodex balance system

Detailed Description

effect of post covid-19 on dynamic balance in patients after recovery from COVID disease.

patients will treated with medical protocol of COVID 19 an out-patient clinic , and followed up by the chest specialist . The balance tests of the patients were performed 2 to 14 weeks after their recovery from the disease, which was confirmed by the evaluations of the COVID staff and negative polymerase chain reaction test.the patients will evaluated using questionnaires. First, the question will whether feeling in balance in the daily life or not. The answer will classified as "yes"or "no". Second, asked to fill "Dizziness Handicap Inventory"(DHI), which is a multidimensional self- assessment scale created to evaluate the effects of dizziness and balance problems on the quality of life as well as the level of disability of the patients. Assess balance , which consists of a movable balance platform that provides up to 20 of surface tilt in a 360 range of motion. The platform is interfaced with computer software that enables the device to serve as an objective assessment of balance . The measure of postural stability includes the overall (OA), the anteroposterior (AP) and the mediolateral (ML) stability scores. A high score in the OA index indicates poor balance. The OA stability score is believed to be the best indicator of the overall ability of the patient to balance the platform

Study Design

Study Type:
Observational
Actual Enrollment :
25 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Evaluation of Dynamic Balance After Recovery From COVID 19 Disease
Actual Study Start Date :
Feb 20, 2022
Actual Primary Completion Date :
Dec 30, 2022
Actual Study Completion Date :
Mar 21, 2023

Outcome Measures

Primary Outcome Measures

  1. overall (OA), the anteroposterior (AP) and the Medio lateral (ML) stability scores [2 to24 WEEKS after their recovery from the disease]

    A high score in the OA index indicates poor balance. The OA stability score is believed to be the best indicator of the overall ability of the patient to balance the platform

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 40 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • 25post COVID-19 patients suffering from inbalance.

  • Age will be ranged from 30 to 40 years old.

  • Body mass index (BMI) will be ranged from 25 to 35 Kg/m2.

  • Diagnosed as COVID-19 patients with a positive reverse transcription polymerase chain reaction (RT-PCR) result of SARS-CoV-2, or typical computerized tomography (CT) evidence of viral pneumonia.

  • All enrolled patients with moderate covid-19 infection.

Exclusion Criteria:
  • Severe disease or hospitalization at intensive care units will excluded from the study.

  • Patients with previous hearing problems or balance disorders.

  • Patients who had ear surgery, cardiovascular and circulatory problems,.

  • Patients with orthopedic problems in the lower extremities due to other problems

  • Patients with Any history of neurological or psychiatric disease, severe visual or auditory impairments.

  • Diabetic patients.

Contacts and Locations

Locations

Site City State Country Postal Code
1 October 6 u El-Sheikh Zayed City Giza Egypt 1133

Sponsors and Collaborators

  • October 6 University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amira Mohamed Afify, Associate professor, October 6 University
ClinicalTrials.gov Identifier:
NCT05813886
Other Study ID Numbers:
  • P.T.REC/012/003590
First Posted:
Apr 14, 2023
Last Update Posted:
Apr 19, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2023